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Abstract: Reactive oxygen species (ROS) and mitochondria play a pivotal role in regulating platelet
functions. Platelet activation determines a drastic change in redox balance and in platelet metabolism.
Indeed, several signaling pathways have been demonstrated to induce ROS production by NAPDH
oxidase (NOX) and mitochondria, upon platelet activation. Platelet-derived ROS, in turn, boost further
ROS production and consequent platelet activation, adhesion and recruitment in an auto-amplifying
loop. This vicious circle results in a platelet procoagulant phenotype and apoptosis, both accounting
for the high thrombotic risk in oxidative stress-related diseases. This review sought to elucidate
molecular mechanisms underlying ROS production upon platelet activation and the effects of an
altered redox balance on platelet function, focusing on the main advances that have been made
in platelet redox biology. Furthermore, given the increasing interest in this field, we also describe
the up-to-date methods for detecting platelets, ROS and the platelet bioenergetic profile, which have
been proposed as potential disease biomarkers.
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1. Introduction
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are highly reactive molecules,
generated in response to both endogenous and exogenous stimuli. The most important cellular
ROS/RNS include both radical and non-radical oxygen-based molecules, as superoxide anion (O•2-),
hydrogen peroxide (H2O2), hydroxyl radical (•OH), hydroxyl ion (OH−), as well as nitrogen-based
molecules including nitric oxide (•NO), nitrogen dioxide radical (•NO2) and peroxynitrite (ONOO-) [1,
2]. ROS are physiologically produced by NADPH oxidase (NOX), a cell membrane enzymatic complex,
and by mitochondria as products of the electron transport chain (ETC), and act as second messengers
regulating several signaling pathways [3]. The cellular concentration of ROS is regulated by enzymatic
and non-enzymatic antioxidant systems to maintain cellular redox balance. The imbalance between
ROS production and antioxidant mechanisms, due to increased ROS production and/or decreased
antioxidants activities, results in oxidative stress that promotes protein, lipid and DNA damage [4].
Oxidative stress is considered a common pathophysiological mechanism and it has been associated
to many pathological conditions such as cancer [5,6], diabetes [7–10], cardiovascular [11,12] and
neurodegenerative diseases [13,14].
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Platelets are anucleated cells derived from megakaryocytes (MKs), which play a crucial role
in hemostasis, thrombus formation, atherosclerosis, inflammation and immune response [15–17].
Human thrombopoiesis is finely tuned, since the number and function of circulating platelets are
essential to maintain hemostasis [18–24]. Indeed, while excessive platelet release (thrombocytosis)
and activation (platelet hyperreactivity) are usually associated with a higher thrombotic risk [25],
reduced platelet counts (thrombocytopenia) and altered platelets function, due to inherited or acquired
defects [26], might compromise wound healing, resulting in an increased risk of bleeding and
hemorragic disorders [27].
The pivotal role of ROS and mitochondria in platelet function has recently emerged, regulating
platelet activation, aggregation and recruitment, tuning several cellular signaling pathways. [28–30].
This aspect is even more relevant if we consider that platelets are both source and target of ROS
(Figure 1).
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Several studies suggested that MKs differentiation as well as platelet release and activation are 
modulated by extracellular ROS in a microenvironment-dependent manner [31]. Upon activation, 
agonists stimulation triggers signaling pathways that result in the production of ROS by both 
NAPDH oxidases (NOXs) and mitochondria [32,33]. The increased production of endogneous ROS, 
in turn, alters mitochondria function and boosts platelet activation in an auto-amplifying loop [34]. 
Despite changes in redox status occur physiologically during platelet activation, the onset of 
oxidative stress conditions can modify platelet function and lead towards two main pathological 
outcomes: toxicity and hyperactivation. In turn, toxicity results in excessive platelet apoptosis and 
Figure 1. Schematic representation of the relationships between platelet functions and redox state.
Activated platelets produce ROS, via NOX1/2 signaling activation and induction of mitochondrial
dysfunctions. Intra- or extra-platelet ROS boost platelet activation by regulation of: platelet receptors
function, bioavailability of platelet agonist or inhibitors, isoprostanes formation and low-density
lipoproteins (LDLs) oxidation.
Several studies suggested that MKs differentiation as well as platelet release and activation are
modulated by extracellular ROS in a microenvironment-dependent manner [31]. Upon activation,
agonists stimulation trigger signaling pathways that result in the production of ROS by bo h NAPDH
oxi ases (NOXs) and mitochondr a [32,33]. The increased production of endogneous ROS, n tur ,
lters mitochondria function and boosts platelet activation in an auto-amplifying loop [34].
espite changes in redox sta us ccur physiologically during latele activation, th onset of
oxidative st ess c nditions ca m dify platelet function and lead towards two main pathological
outcomes: toxicity and hyperactivation. In turn, t xicity results i excessive platelet apoptosi and
therefore in thrombocytopenia and bleeding while, hyperactivation may le d to excessive clot formation
and thromb embolic complications.
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Oxidative stress has been described in several disorders including atherosclerosis, diabetes
mellitus, hypertension, obesity, and cancer [35,36]. In these pathological settings, oxidative stress is
the secondary outcome of the diseases; the increased oxidative burden in the circulation exposes platelets
to a pro-activatory milieu, responsible for platelet pro-adhesive and pro-aggregatory phenotype, which
in turn lead to thromboembolic propensity, a common characteristic of all these diseases. In turn,
oxidative stress-activated platelets are a source of ROS, which further contribute to the circulating
oxidative stress. This process generates a vicious circle capable to affect other cell types, eventually
contributing to diseases progression and complications.
2. Sources of ROS in Platelets
Nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) oxidases (NOX) isoforms are
the main sources of ROS in platelets, followed by cyclooxygenase (COX), xanthine oxidase (XO)
and mitochondrial respiration [37]. NOX enzymes are able to transport electrons from NADPH across
biological membranes to reduce oxygen to superoxide (O•2-). The NOX family is composed of seven
different isoforms including NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1, and DUOX2; they differ
in activation, subunit composition, localization, and expression. All members have six predicted
transmembrane domains, motifs for NADPH and FAD (flavin adenine dinucleotide) binding, and
conserved paired histidines able to bind to heme groups [38].
In human platelets, both NOX1 and NOX2 significantly contribute to ROS production, and they
are considered responsible for the regulation of platelet responsiveness [39]. Both isoforms are inactive
in resting platelets and turn on upon stimulation by agonists, forming a multi-complex with several
regulatory cytoplasmic subunits. NOX2 forms a multiprotein complex with p22phox, p40phox, p47phox,
p67phox and the small GTPase Rac1. NOX1 also interacts with similar proteins, including p22phox,
NOXO1 (similar to p47phox), NOXA1 (similar to p67phox), and GTPase Rac1 [40]. The translocation
of cytoplasmatic subunits is driven by the protein kinase C-dependent phosphorylation of p47phox
and NOXO1; and their subsequent interaction with both p22phox (via a Src homology-3, SH3 domain)
and the membrane-associated phosphatidylinositol 3-kinase (PI3K) product, phosphatidylinositol
3,4-biphosphate, PI(3,4)P (via a phox homology PX domain). GTPase Rac1 plays a pivotal role in
both NOX1 and NOX2 activation, orchestrating the assembly of the active enzyme complex. Indeed,
Rac1-GTP binding to p67phox and to NOXA1 facilitates, in turn, complex formation with NOX2
and NOXA1, respectively, and their functional activation [41]. Recently, small-molecule inhibitors
of Rac1–p67phox interaction have been designed in order to prevent ROS production. These small
molecules have been validated in vitro and in vivo, and have been proposed as potential anti-thrombotic
therapies to reduce platelet hyperactivation and aggregation without affecting the hemostatic response
to injury [42].
NOX activity has been correlated to platelet responsiveness in physiological and pathological
conditions. Indeed, impaired platelet activation has been described in patients with genetically
determined NOX2 deficiency. Pignatelli and colleagues studied platelet activation in X-linked
chronic granulomatous disease (X-linked CGD), a rare primary immunodeficiency affecting the innate
immunological system, frequently associated with severe infectious diseases. Patients with X-linked
CGD, genetically deficient in NOX2 (gp91phox), showed defects in platelets, ROS generation and CD40
ligand expression, upon thrombin, collagen, and arachidonic-acid platelet activation [43]. Recently,
similar results were obtained in patients with hereditary deficiency of the p47phox subunit, but with
milder effects on platelet activation [44]. Treatment of human platelets with non-specific NOX inhibitors
phenocopies the effects of ROS scavengers, leading to a significant reduction in intracellular ROS,
platelet aggregation and thrombus formation under high shear [45,46].
The differential involvement of NOX isoforms seems to be stimulus-specific, based on the nature
of the agonist that triggers platelet activation. Indeed, Delaney and colleagues, comparing NOX1
and NOX2 isoform activation in a knock-out murine model, demonstrated that NOX1 was selectively
involved in platelet aggregation and ATP secretion, in response to thrombin and thromboxane A2
Int. J. Mol. Sci. 2020, 21, 4866 4 of 34
analog U46619. By contrast, NOX2 was activated in GPVI/ITAM-mediated platelet activation as well as
in GPCR-induced calcium mobilization. NOX2−/− mice had a severe and significant defect in adhesion
and recruitment of platelets at the site of laser-induced arteriolar wall injury, suggesting that NOX2,
but not NOX1, is involved in thrombus formation [47].
In contrast with this study, Walsh and colleagues suggested that NOX2 had no relevant role in
response to collagen, with NOX1 playing the main activating role in the signaling of the collagen-specific
GPVI receptor [48]. Recently, the different roles of NOX1 and NOX2 have been investigated using
NOX-selective peptide inhibitors and a novel technique to simultaneously monitor platelet activation
and oxygen-radical generation [49]. It has been demonstrated that in human platelets, NOX1 is the main
source of ROS in response to collagen, while NOX2 is critical for the activation induced by thrombin.
Indeed, dismutation of NOX2-derived O•2- to H2O2 is the main stimulus for platelet-dependent
thrombus stabilization. Moreover, both NOX1 and NOX2 are activated by oxidized low-density
lipoprotein (ox-LDL) and amyloid-β peptide (Aβ1-42), both capable of modulating platelet function
and both associated with the thrombotic complications of atherosclerosis [50] and cerebrovascular
amyloid angiopathy (CAA), respectively [51].
NOX-dependent ROS production can, in turn, trigger additional ROS generation by platelet
mitochondria. The ubiquinone-binding sites in complex I and III of the ETC have been identified
as the main mitochondrial sources of O•2-, which can then be converted into H2O2 by superoxide
dismutase 2 (SOD2) [29]. Mitochondrial ROS production is mainly regulated by the redox state of
the ETC, and therefore by mitochondrial membrane potential (∆Ψm) [29]. Hyperpolarization of
the mitochondrial membrane is associated with ROS production and platelet activation [52]. Indeed,
mitochondria production of ROS observed upon hyperglycemia, a condition often associated with
type 2 diabetes mellitus, is due to the increase in ∆Ψm and determines platelet aggregation. In
this model, the inhibition of ETC complexes completely abolishes ROS production and platelet
activation [53]. On the other hand, depolarization of mitochondrial membrane potential is a key step
in the procoagulant-platelet microparticle formation [54].
3. Platelet Activation Triggers ROS/ Production
In physiological conditions, platelets respond with a functional triade of adhesion, activation and
aggregation. Platelet adhesion is mediated by the interaction of platelet glycoprotein VI (GPVI) and
GPIbα, with collagen and von Willebrand factor (VWR), respectively [55]. This process triggers platelet
activation typified by cytoskeletal and membrane rearrangements, shape change, calcium mobilization
activation of the platelet integrin αIIbβ3 (GPIIb–IIIa) [56] degranulation and phosphatidylserine (PS)
externalization [56].
The release of adenosine diphosphate (ADP), factor V, fibrinogen, thrombin, and thromboxane A2
(TXA2) from platelet granules contributes to the amplification of platelet and to the recruitment of
additional platelets at the site of growing thrombus. The interaction between fibrinogen and activated
integrin αIIbβ3 [57], expressed on activated platelet, induces platelet aggregation and stabilizes
the hemostatic plug, through the conversion of fibrinogen to fibrin by thrombin [56].
Oxidative stress and persistent stimuli lead to excessive platelet activation, which typify several
pathological conditions including myocardial infarction, stroke, atherothrombosis and metabolic
disorders [35].
Platelet intracellular ROS are produced at the basal state by NOX1/2 isoforms, and rapidly increase
upon platelet-receptor stimulation (Figure 2).
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GPVI is a type I transmembrane receptor of the immunoglobulin (Ig)-like superfamily, and its
cytoplasmatic tail [60] can bind calmodulin (CaM) and Src family kinase, including Fyn and Lyn, key
components for the propagation of signals downstream of GPVI receptor [61]. GPVI forms a complex
with the Fc receptor γ-chain (FcRγ), that contains an immunoreceptor tyrosine-based activation motif
(ITAM). Collagen binding to GPVI/FcRγ complex results in the phosphorylation of ITAM by Lyn and
in the activation of spleen tyrosine kinase (Syk) and phosphatidylinositol 3-kinase (PI3K), leading
to the activation of phospholipase Cγ2 (PLCγ2)-IP3/PKCs (protein kinase C) signaling pathway. As
a consequence, inside-out activation of integrin αIIbβ3 (GPIIb/IIIa) and α2β1 (GPIa/IIa) takes place,
mediating platelet aggregation and activation of metalloproteinase-mediated shedding of GPVI [28,62].
Of note, GPVI cytoplasmatic domain might also bind tumor necrosis factor associated factor 4 (TRAF4),
which is thought to interact with p47phox, a subunit of the NOX1 and NOX2 complex [63].
Two distinct phases of ROS generation have been proposed upon collagen-mediated GPVI
activation [63]. The initial phase is Syk-independent: TRAF4 allows the interaction of Lyn with (PKCδ),
which, in turn, phosphorylates p47phox, inducing NOX-mediated ROS production. TRAF4 can also
bind other signaling proteins, such as Hic-5 (focal adhesion adapter protein) and Pyk2 (proline-rich
tyrosine kinase 2), which are constitutively associated with Lyn. This TRAF/p47phox/Hic-5/Pyk2/NOX
axis is thought to be responsible for the rapid burst of ROS [64]. The second phase is Syk-dependent:
ligand-induced activation of ITAM leads to Syk activation, which results in the stimulation of
the (PLCγ2)-IP3/PKCs axis; lastly, PKCs can activate NOX, supporting the subsequent production of
ROS [65].
A similar biphasic mechanism has also been observed in mitochondrial ROS production, in
which an initial phase, termed ROS-induced ROS release (RIRR), is followed by a second phase of
amplification of ROS release [66].
As mentioned above, PI3K is involved in collagen-induced ROS generation and platelet aggregation.
The activation of PI3-K is considered essential for maintaining GPIIb-IIIa and supporting aggregation.
Platelets express various PI3K isoforms. The class I PI3Ks, especially PI3Kβ and PI3Kγ, have been
widely investigated in arterial thrombosis and cardiovascular disorders, and they are involved in
platelet signal transduction during activation [67]. Recently, class III PI3K α (PI3KC2α) has also been
identified in this process, playing a critical role in NOX complex assembly and O•2- production, with
PI3KC2α−/− mice showing decreased levels of ROS, reduced shear-dependent platelet adhesion and
thrombus stability [68].
In contrast to collagen, thrombin seems to be involved in the production of extracellular ROS.
Thrombin is a potent platelet mediators that acts via G protein–coupled receptors, as GPIbα and protease
activated receptors (PAR1 and PAR4) [69]. Thrombin-stimulated platelets generate extracellular ROS,
through the activation of a signaling pathway mainly involving PAR4 and GPIbα binding, and induce
NOX1-dependent production and release of O•2-, which further amplifies the initial signals and
sustains platelet recruitment and activation [58].
Furthermore, TXA2, has also been implicated in platelet ROS production and release [37,45,
70]. During the conversion of arachidonic acid into TXA2 in activated platelets, cyclooxygenase 1
(COX1) catalyzes the formation of intermediate prostaglandin H2 (PGH2), and generates ROS as
a by-product [71]. Then TXA2 is released to promote thrombus growth by recruiting additional
platelets. Upon their interaction with TP receptors, TXA2 and its synthetic analog, U46619, they
increase intracellular Ca2+ concentration, which is required for Src phosphorylation and NOX-derived
ROS generation. In this model, ROS production is completely abolished with NOX inhibitor apocynin
and calcium chelator BAPTA, while it is only reduced in platelets treated with the Abl/Src inhibitor
dasatinib, and subsequently stimulated with TXA2 agonists [72].
In addition to collagen/GPVI and thrombin/PAR4, NOX2 can be also activated by sCD40L/CD40
and ox-LDL/CD36 interaction. CD40 ligand (CD40L or CD154) is a transmembrane protein stored in
platelet α-granules. After platelet activation, CD40L is expressed on platelet membrane and it can be
cleaved by metalloproteinases and released into a soluble form (sCD40L) [73] that may activate platelets
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binding CD40 and αIIbβ3, [74]. sCD40L binding with both receptors induces Akt and p38 MAP
kinase phosphorylation. Chakrabarti and coworkers demonstrated that inhibition of NOX decreased
the generation of ROS in platelets stimulated with recombinant sCD40L, and identified the Akt-p38
MAP kinase axis as the signaling pathway associated with sCD40L-dependent NOX activation [2].
Ox-LDLs are known to promote platelet hyperactivity and platelet pro-thrombotic phenotype in
dyslipidemic disorders and cardiovascular diseases [75]. Ox-LDLs exert their function binding two
different platelet receptors: CD36, which is constitutively expressed on platelet membrane, and LOX1
expressed only upon activation. The deletion of these receptors in animal models of artery thrombosis
has been associated to a marked reduction in thrombus formation [76,77]. Magwenzi and colleagues
have recently demonstrated that ox-LDL/CD36 binding induced the activation of a tyrosine kinase and
PKC-signaling that led to NOX2-mediated ROS generation. Ox-LDL-induced ROS generation was
markedly reduced by pharmacological inhibition of NOX2 (gp91ds-tat) and completely abolished in
CD36−/− and NOX2−/− mice [78].
4. Endogenous and Exogenous Antioxidant Systems as Regulators of Platelet Function
Antioxidants play an important role in maintaining redox balance in platelets. Platelets have
a number of antioxidant defenses that include antioxidant proteins, which show enzymatic activity,
and non-enzymatic molecules able to rapidly neutralize ROS [35]. Enzymatic antioxidants include
superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-S-transferase
(GST) and nitric oxide synthase (NOS), while and non-enzymatic antioxidants consist of glutathione,
vitamins, carotenoids, polyphenols, and some other molecules [79].
Since platelets, upon activation, produce ROS which, in turn, enhances platelet activation, it
is clear that antioxidants can not only prevent the cytotoxic effects of ROS, but can also regulate
redox-sensitive signaling pathways in platelets [35]. Antioxidants exert their anti-thrombotic effects by
directly converting ROS into more stable molecules, and indirectly increasing NO.
4.1. Endogenous Platelet Antioxidant
The first major defense component of the antioxidant system is represented by SOD. SODs are
a family of enzymes that catalyzes the dismutation of O•2- in oxygen and H2O2. SOD family consists
of three isoforms with a different cellular localization and metal cofactor: homodimeric Cu/Zn-SOD
(SOD1), localized in the cytosol and in the mitochondrial intermembrane space; homotetrameric
Mn-SOD (SOD2), localized in the mitochondrial matrix and homotetrameric Cu/Zn-SOD (SOD3) with
an extracellular distribution. Platelets express both SOD1 and SOD2. SOD plays an important role
in physiological platelet function and in prevention of thrombus formation, promoting endogenous
nitric oxide (NO)-bioactivity [80]. In vitro experiments showed that administration of SOD, as well
as N-acetylcysteine (NAC), a synthetic inhibitor of ROS, completely abolished O•2- production
and collagen-mediated platelet activation. Furthermore, SOD phenocopied the effects of the NOX
inhibitor, DPI (diphenyleneiodonium chloride), impairing platelets aggregation [46]. The effects on
platelets activation were mainly attributed to the cytosolic SOD1 activity, since SOD2 specially acts on
mitochondrial-derived ROS. Recently, Fidler and coworkers demonstrated that SOD2-KO platelets
showed increased mitochondrial ROS; however, total platelet ROS content remained unchanged.
Furthermore, deletion of SOD2 did not alter tail-bleeding or arterial thrombosis in vivo, suggesting
that SOD2 is dispensable for platelet redox balance [81,82].
SOD produces H2O2 which is a more stable molecule than O•2-; additionally, while O•2- is
charged, hardly permeable and short-lived, H2O2 is uncharged, diffusible and has a longer half-life [83].
H2O2 may act as a second messenger inducing intracellular calcium mobilization, arachidonic acid
and TXA2 release and phospholipase C up-regulation in platelets [59].
H2O2 is efficiently neutralized by both CAT and GPx. Platelets derived from GPx1/CAT
double-deficient mice showed elevated cellular ROS levels and enhanced PLCγ2 activation in response
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to collagen, which subsequently led to increased intracellular calcium levels, degranulation, and
integrin αIIbβ3 activation [84].
GPx are a family of selenocysteine-containing enzymes, which use glutathione as a mandatory
co-substrate. GPx catalyzes the reduction of hydrogen and lipid peroxide in water and lipid alcohols,
oxidizing glutathione (GSH) to glutathione disulfide (GSSG) in the process [85]. Glutathione peroxidase
is tightly coupled to glutathione reductase, a NADPH-dependent enzyme, that restores reduced GSH.
In platelets, GSH depletion attenuates GPx activity and induces an increase in lipid peroxidation,
altering the redox homeostasis [35]. In murine models, GPx deficiency is associated to an increased
risk of platelet-dependent thrombosis and vascular dysfunction, due to an impaired ROS metabolism
and a decreased NO-mediated platelet inhibition [86].
H2O2 decomposition could be also catalyzed by the thiol-selenoperoxidase peroxiredoxins. These
enzymes and, in particular, peroxiredoxin II (PrxII) negatively regulate various receptor signaling
pathways in response to platelet-derived growth factor, epidermal growth factor, or T cell ligands.
Recently, the antioxidant function of PrxII has been correlated with platelet activation by Jang’s research
group [87]. Indeed, it has been demonstrated that PrxII acts as a negative modulator of GPVI-mediated
signaling, by eliminating platelet H2O2; depletion of this antioxidant enzyme is associated with
a pro-thrombotic platelet phenotype. These results have also been validated in in vivo experiments
showing that PrxII-KO mice are more inclined to develop platelet-dependent thrombus formation after
carotid artery injury [87].
Reduced/oxidized nicotinamide adenine dinucleotide (NADH/NAD+) and reduced/oxidized
nicotinamide adenine dinucleotide phosphate (NADPH/NADP+) couples are closely linked to
glutathione (GSH), protein disulphides isomerases (PDIs), thioredoxin (Trx) and PrxII. Indeed,
these pyridine nucleotides, take part in ROS generation by NOX, and regulate oxidation/reduction
balance. Trx- and glutathione- reductase, for instance, use NADPH as an electron donor to convert
the oxidized forms of Trx and glutathione (GSSG) into their reduced states. The NADPH/thioredoxin
reductase/thioredoxin system regulates the thiol profile of key platelet adhesion/activation
receptors and influences platelet reactivity to collagen (GPVI-pathway) and von Willebrand factor
(GPIb-IX-V-pathway) [88].
Glutathione is the main non-enzymatic antioxidant within cells. Glutathione presents
a redox-active thiol group thiol group [sulfhydryl (-SH) group in the cysteine residue], that becomes
oxidized (GSSG) when GSH reduces target molecules. The extra- and intracellular ratio of the reduced
form (GSH) to the oxidized form (GSSG) is indicative of oxidative stress in various cells [89]. GSH
exerts its antiplatelets effects regulating platelet TXA2 synthesis [90], and enhancing the antiplatelet
activity of S-nitrosoproteins. Low GSH/GSSG ratio has been associated with greater susceptibility of
platelet to activating agents [91].
4.2. Exogenous Redox Systems
Platelets may be also affected by the surrounding microenvironment, including blood cells, vascular
endothelial cells, vascular smooth muscle cells and fibroblasts. In physiological conditions, resting
state of platelets is preserved by endothelial production of •NO and prostacyclin [92]. Endothelial- and
platelet-derived •NO is also essential for limiting platelet activation and thrombus growth following
tissue damage, and recovering normal homeostasis. In pathological conditions or under oxidative
stress, vascular endothelium, activated macrophages, neutrophils and damaged erythrocytes release
elevated amounts of ROS, which boost proinflammatory and procoagulant platelet functions. •NO
antiplatelet effects are impaired upon the reaction with O•2-, which generate peroxynitrite.
Vascular antioxidants systems (SOD, CAT, GPx, glutathione S-transferases, Prx and heme
oxygenase 1, HO-1) and extracellular antioxidant compound, as GSH/GSSG and GPx3, could directly
or indirectly, contribute to limit the ROS/RNS-mediated oxidative reactions in platelets and to restore
the redox balance [93]. Extraplatelet SOD and CAT inhibit αIIbβ3 activation and P-selectin expression
after thrombin stimulus. The extracellular isoform of GPx, GPx-3, can scavenge reactive oxygen species
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in the extracellular compartment and enhance •NO bioavailability [94]. Moreover, in the murine
model, GPx-3 deficiency has been associated with platelet-mediated arterial thrombosis [95]. Recently,
the plasmatic GSH/GSSG ratio has emerged as a regulator of platelet function, controlling the activation
of platelet membrane PDIs (platelet disulfide isomerase). Indeed, the balance between dithiol and
disulfide fractions at the active site of PDI, regulates the activation of platelet GP IIb/IIIa and GPIb
integrins, ensuring high-affinity binding [93].
In addition, exogenous antioxidants derived from the diet including vitamin E, vitamin
C, carotenoids, some minerals (Zn, Mn, Cu, Se) and polyphenols (flavonoids, phenolic acids,
stilbenes, lignans), act as non-enzymatic scavengers preserving redox balance and regulating
platelet functions [79]. These antioxidants are present in fruits, vegetables, commonly consumed
beverages (juices, tea, coffee, wine), extra virgin olive oil, nuts, cereal products and cocoa [96]. Many
epidemiological studies have pointed out that a diet rich in polyphenols reduces the susceptibility to
various diseases, such as diabetes, and Alzheimer’s disease [97,98], and they have been associated with
a low risk of thrombotic events and cardiovascular mortality [99]. The beneficial effects of polyphenols
are in part related to their antioxidant and anti-thrombotic properties. Polyphenols in cocoa and extra
virgin olive oil can regulate platelet function, as demonstrated by the inhibitory effect of polyphenol-rich
nutrients on platelet activation [100]. Catechin and epicatechin from cocoa and polyphenols from extra
virgin olive oil exert their antiplatelet effect through the down regulation of NOX2 and the consequent
reduction in the formation of ROS [101–103]. Polyphenols could also enhance •NO generation and/or
bioactivity, which leads to inhibition of platelet activation and could trigger the Nrf2-Keap1 (nuclear
factor erythroid-2 related factor 2/kelch-like ECH-associated) axis, which in turn leads to the activation
of the antioxidant response element [104]. In addition to polyphenols, vitamin E (alpha-tocopherol)
and vitamin C (ascorbic acid) have anti-platelet and anticoagulant properties [105]. In particular,
the antiplatelet activity of vitamin C is mainly due to its capacity of quenching superoxide radicals [106].
5. Redox Control of Platelet Activation
Platelet-derived ROS act as second messengers and can influence different signaling pathways
which enhance agonist-induced platelet function. Although the exact molecular mechanisms by which
ROS affect platelet function are still under investigation, NOX-derived ROS have been suggested to
regulate: (i) platelet receptor activity; (ii) bioavailability of both platelet agonists and inhibitors; (iii)
isoprostane formation; (iv) LDL oxidation (Figure 3).
Oxidative changes occurring inside platelets after activation seem to modulate platelet receptor
function, including αIIbβ3, GPIbα and GPVI [45,107–109].
TheαIIbβ conformational change, leading to fibrinogen binding and platelet-platelet interaction, is
blocked by NOX inhibitors and superoxide scavengers, though a NO/cGMP-independent pathway [45].
The role of platelet-derived extracellular ROS in integrin αIIbβ3 activation is still unclear. It has
been proposed that extracellular ROS can interact with thiol groups present in the extracellular
domain of αIIbβ3, promoting integrin activation [93]. These data suggest the direct role of redox
systems in thrombin-induced αIIbβ3 activation. Moreover, in a recent study by Kim et al., platelet
NOX2-produced ROS regulated P-selectin exposure upon thrombin stimulation and ligand-binding
function of GPIbα. ROS induced the oxidation of GPIbα sulfhydryl groups promoting platelet adhesion
and platelet–leucocyte interaction [107].
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Figure 3. Redox control of platelet activation. NOX-derived ROS boost further R S production and
the consequent platelet activation, adhesion and recruitment in an auto-amplifying loop. Intraplatelet
and extracellular ROS regulate platelet receptor (GPIbα and αIIbβ3) binding affinity and GPVI and
GPIbα shedding via ADAMs. NOX-derived ROS also regulate ADP and •NO bioavailability, α granules
release and P-selectin exposure on platelet membrane. ROS potentiate the PLCγ/PKC/MAPKp38
signaling cascade, thereby inducing PLA2 activation and 8-iso-PGF2α formation. ROS upregulate
CD40L surface expression and release in response to platelet agonists. Upon secretion in the vascular
lumen, platelets-derived ROS promote the oxidation of circulating LDL. NOX-derived ROS induce
mitochondrial dysfunction. (NOX: NAPDH oxidase; GPIbα: glycoprotein Ibα; αIIbβ3: glycoprotein
GPIIb/IIIa; GPVI: glycoprotein VI; ADAM: disintegrin and metalloproteinase; ADP: adenosine
diphosphate; NO: nitric oxide; PLCγ: phospholipase Cγ2; PKC: protein kinase C; MAPKp38: P38
mitogen-activated protein kinases; PLA2: phospholipase A2; 8-iso-PGF2α: 8-iso-prostaglandin F2α;
CD40L: CD40 ligand; LDL: low-density lipoprotein).
Furthermore, ROS are involved in the mechanism of platelet receptor shedding that reduces platelet
adhesive capacities and results in platelet dysfunction. However, it has been recently demonstrated
that platelet receptor shedding increase coagulation factor binding and enhance thrombin and
fibrin generation, which result in a platelet procoagulant phenotype [110]. Platelet activation is
closely associated to GPVI and GPIbα shedding and ectodomain release in plasma. This event is
mediated by the activation of metalloproteinases (ADAMs). ADAMs are a family of disintegrins and
metalloproteinases that catalyze the cleavage of the ectodomains of GPVI and GPIbα. In particular,
it is considered that ADAM17 primarily cleaves GPIbα, whereas ADAM10 predominantly acts on
GPVI [111,112]. Interestingly, ROS can oxidize cysteine residues located on the cysteine-rich domains of
ADAMs and/or interact with intracellular cytoplasmic domains of these metalloproteinases, promoting
their activation [113]. Furthermore, ROS induce GPIbα shedding trough the oxidation of cysteine
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residues of different protein kinases including p38-MAPK, known to active ADAM17 [109]. Recently,
Hosseini and coworkers demonstrated that receptor shedding is partially inhibited when activated
platelets are treated with reducing agents such as NAC or DTT, suggesting a role of ROS in this
process [113].
ROS are also thought to regulate GPVI signaling cascade in a redox-dependent mechanism, and to
consequently boost NOX related ROS production. Indeed, ROS produced upon collagen stimulation,
prevent Src homology region 2-containing protein tyrosine phosphatases 2 (SHP-2) inhibition of GPVI
signaling through the direct oxidization of the catalytic cysteine of SHP-2 [84].
Platelet-derived O•2- upregulates CD40L surface expression and release in response to platelet
agonists, as thrombin and convulxin. On the contrary, antioxidants (such as extracellular SOD and
vitamin C) as well as NOX inhibitors significantly inhibit CD40L upregulation [114]. Similarly, in
patients with an inherited deficiency of gp91phox (the catalytic core of NOX) the expression of O•2-
and CD40L expression by activated platelets have been found almost completely suppressed [43].
However, the molecular mechanism(s), that underlie intra- and extra-cellular ROS effects on CD40L,
remains unknown.
In addition to CD40L upregulation, ROS have been found to modulate platelet α-granule
exocytosis. Indeed, Bakdash and colleagues demonstrated that NAC and synthetic antioxidant
compounds significantly inhibited surface membrane expression of CD62p and RANTES release in
thrombin activated platelets [58].
ROS regulate the bioavailability of platelet agonists and inhibitors as ADP and •NO.
Platelet-derived O•2- has been demonstrated to support platelet recruitment by increasing ADP.
Collagen stimulation induces a strong release of ADP, but the amount of ADP in supernatants of
collagen-stimulated platelets were decreased in presence of SOD. Therefore, Krotz and coworkers
suggested that collagen-induced O•2- may inactivate platelet ADP-destroying ectonucleotidase and
thereby extend ADP availability and function [46]. •NO produced by both endothelial cells and
platelets is a potent inhibitor of platelet aggregation through the activation of a NO-sensitive guanylyl
cyclase (NO-GC) [115]. The O•2- can rapidly react with •NO to form ONOO-, decreasing •NO
availability and thereby abolishing its antiplatelet function. The role of NOX in counterbalancing
•NO activity was recently confirmed in patients with chronic granulomatous disease in which NOX
genetic deficiency determined complete suppression of platelet O•2- production and increased levels
of •NO [116].
Intra-platelet ROS contribute to lipid peroxidation that leads to the formation of isoprostanes.
The 8-iso-PGF2α is considered a gold-standard biomarker of oxidative stress, and elevated levels
have been found in the plasma and urine of patients with cardiovascular disorders [117–119],
atherosclerosis [120,121], type 2 diabetes mellitus [122,123] and hypertension [124]. Upon stimulation,
platelets release 8-iso-PGF2α primarily via nonenzymatic oxidation of AA catalyzed by NOX-derived
O•2-. Accordingly, NOX2-deficient patients with CGD show an impaired ROS production and
a decrease in platelet 8-iso-PGF2α levels. A similar inhibition of isoprostanes was described in platelets
treated with the NOX2 inhibitor apocynin [116].
Finally, platelet-derived ROS, secreted in the vascular lumen, are involved in the oxidation of
circulating LDL. High plasma concentrations of ox-LDL have been found in patients with Type 2
diabetes mellitus as consequence of hypercholesterolemia and hyperglycemia, and they have been
correlated with cardiovascular events [125,126]. Recently, activated platelet have been demonstrated to
promote in vitro LDL oxidation; indeed, incubation of activated platelets with both purified LDL and
homogenized atherosclerotic plaque resulted in a marked increase in ox-LDL levels. The oxidation
of LDL was significantly inhibited by NOX specific inhibitors and aspirin and was not observed in
platelet of CGD patients, suggesting the involvement of NOX2 and ROS in this process [127].
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6. Role of Platelet Mitochondria in Redox Balance
Platelets are considered the most metabolically active circulating cells under basal conditions [128]
and mitochondria have been considered for decades as the main energy source to support platelet
function on platelet function.
In resting platelets, approximately 60% of ATP is provided by glycolysis while only the remaining
40% is produced during the oxidative phosphorylation (OXPHOS) [128]. Platelets ability to promptly
respond to stressors or agonists, is associated to an extraordinary energy demand. Therefore, platelet
activation seems to markedly alter platelet metabolism, resulting in integrated energetic response to
both glycolysis and OXPHOS [129].
Platelet activation experiments, performed in hypoxic conditions, have demonstrated that
oxidative energy is essential to guarantee optimal platelet functionality, and anaerobic glycoysis
only partially compensates impaired OXPHOS [130–132]. Furthermore, Tomasiak et al. showed that
alterations of mitochondrial complex III (cytochrome oxidase) or mitochondrial complex IV, mediated
by NO, reduce mitochondrial ATP production, resulting in the inhibition of platelet aggregation and
secretion [133].
However, mitochondria are not only involved in energy supply, but they play a crucial role in
platelet activation and apoptosis, regulating redox balance. Indeed, OXPHOS inevitably leads to
mitochondrial O•2- production and release, mainly by complex I and III of the ETC, thus rendering
mitochondria themselves an important source of ROS [134]. Mitochondrial O•2- can be then converted
in H2O2 by SOD2 [29]. Different research groups have demonstrated that platelet activation by
collagen and thrombin induces a rapid and transient increase in the mitochondrial membrane potential
(∆Ψm) and OXPHOS, likely via Ca2+ mobilization [135,136]. The increase in ∆Ψm is associated to
the increased production of ROS in mitochondria, and hyperpolarization of the membrane reduces
the electron transport chain, resulting in a leakage of electrons from the chain followed by promotion
of the production of O•2- [137]. Furthermore, hyperglycemia plus collagen has been related to
the hyperpolarization of platelet mitochondria, resulting in ROS generation and subsequent activation.
In platelets treated with inhibitors of mitochondrial complex II and uncouplers of OXPHOS, the increase
in mitochondrial ROS, induced by hyperglycemia plus collagen, is completely prevented [53].
Interestingly, a biphasic process, named ROS-induced ROS release (RIRR), has been described in
mitochondrial ROS production, characterized by an initial phase of slow release and a second phase of
amplification of ROS release [66].
This process has been studied in cardiomyocytes, smooth muscle cells and endothelial cells [138,
139].
Indeed, analyzing mitochondrial ROS production kinetics, initial ROS (the so-called “trigger
ROS”) are produced by OXPHOS—rapidly engaged to match metabolic needs—and released in
the cytoplasm. Through a positive-feedback mechanism, ROS trafficking between mitochondria
results in an elevated production of ROS, responsible for the oxidation of essential mitochondrial
components. The consequent ROS burst and release is associated with the collapse of the ∆Ψm
and the formation of mitochondrial permeability transition pores (mPTP) in a calcium-independent
manner [140]. Mitochondria exhibit a sort of “ROS excitability” and can respond to either exogenous
or endogenous ROS, by increasing their own ROS production in a self-promoting cycle [66]. A similar
crosstalk was also observed between mitochondrial ROS and NOX-derived ROS in several cellular
models. In human 293T cells transient ROS production by mitochondria stimulated PI3K which
promote translocation of Rac1 to NOX1 complex and ROS generation [141]. In endothelial cells [142]
and in cardiomyocytes [143], angiotensin II stimulation activated NOX by a PKC-mediated mechanism;
NOX-derived ROS, in turn, decreased ∆Ψm leading to mitochondrial ROS formation. It is possible to
speculate that similar processes occur also in platelets during activation, but the molecular mechanisms
and signaling pathways involved in RIRR and in the crosstalk between NOX and mitochondria need
to be further investigated.
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Platelet activation, ROS increase and the subsequent mitochondrial dysfunction lead to platelet
apoptosis, which has therefore been considered a clearance strategy to eliminate hyper-activated
platelets from the bloodstream/circulation, and it was recently associated with thrombocytopenia in
pathological conditions [144]. It has been demonstrated that low concentrations of platelet agonists
induce only an ‘apoptotic-like events’ [145]. On the contrary, potent platelet agonists, such as thrombin
and ionomycin, determine the formation of mPTPs which results in a drastic depolarization of
mitochondrial membrane and increase in H2O2. Indeed, mPTPs are nonselective multiprotein pores
that cross the inner and outer mitochondrial membranes and cause a rapid collapse of ∆Ψm, due to
the impaired proton shift towards the mitochondrial intermembrane space. The formation of mPTPs
plays a key role in the regulation of platelet activation, inducing platelet transition from an “activated”
to a “highly activated” state typified by vesiculation, high-level phosphatidylserine (PS) externalization
and high-level fibrinogen retention [146]. Furthermore, mPTPs and ROS are associated to the activation
and the translocation of pro-apoptotic protein Bid, Bak and Bax to the mitochondria. These effects
evoked by thrombin are significantly attenuated by catalase, indicating the central role of ROS in
platelet apoptosis [136,147].
Of note, ROS have been suggested to directly alter mitochondrial membrane permeabilization
leading to the release of proapoptotic factors, such as cytochrome C and caspases, into
the cytosol. Indeed, in hyperthermia-induced platelet apoptosis, increased mitochondrial ROS
easily oxidize cardiolipin, an important component of the inner mitochondrial membrane, promoting
mitochondrial translocation of Bax, cytochrome-C release, caspase-3 activation, PS exposure and ∆Ψm
depolarization [148] (Figure 4).
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Figure 4. Platelet mitochondria in redox balance. During oxidative phosphorylation, mitochondria
produce ROS. Complex I and III of ETC (electron transport chain) are the main sources of mitochondrial
ROS, called trigger ROS. Trigger ROS are released in the cytoplasm and, through a positive feedback
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resulted in an elevated production of ROS. The ROS burst and release induce the collapse of
the mitochondrial membrane potential (∆Ψm) and the opening of mitochondrial permeability transition
pores (mPTP). These latter events lead to high-level phosphatidylserine externalization, high-level
fibrinogen retention, release of cytochrome c, activation and translocation of pro-apoptotic protein Bak
and Bax, contributing to platelet procoagulant phenotype and platelet apoptosis.
7. Methods to Assess Platelets Redox Biology
The crucial role of platelets and oxidative stress in cardiovascular disorders and inflammatory
diseases has prompted the research of innovative methods to analyze platelet redox systems, as well as
in order to monitor disease and therapy [128,149].
7.1. Detection of Reactive Oxygen Species Levels
Despite the increasing interest in this field of platelet biology, the development of highly accurate
and specific techniques is still challenging because of the evanescent nature of ROS. ROS half-life varies
from approximately 10–9 s for highly reactive •OH, to 10–5 s for H2O2 [150]. Different methods have
been established that allow the direct or indirect measurement of redox states in platelets, including
spectrophotometry, chemiluminescence, electron spin resonance and spin-trapping [151]. These
techniques are too complex and laborious for routine testing. Therefore, an accurate and standardized
method for platelet ROS detection represents an unmet need with rapid potential clinical transferability.
Here, we briefly present the up-to-date methods for platelet ROS and redox balance assessment,
discussing their advantages and limits in both experimental and clinical settings.
Flow cytometry (FCM) is the most widely used technique to measure intracellular levels of ROS.
Due to its high versatility and reliability, FCM represents the candidate technique for platelet studies.
Thus, FCM can be feasibly employed in research and clinical practice to monitor the response to
anti-aggregation therapies, and to assess thrombotic risk in cardiovascular diseases [26,152–156].
The main advantages of this technique are: (i) the requirement of limited sample volumes (only
5 µL); (ii) the possibility to perform the analysis either on freshly isolated platelets, whole blood
or platelet concentrates, with minimal sample manipulation [26]; (iii) the ability of simultaneous
single-shot analysis of several parameters including platelet phenotype, function, activation markers,
platelet–monocyte and platelet–leucocyte interaction, and apoptosis.
Concerning platelet ROS, several fluorescent probes have been developed, with different degrees
of specificity and sensitivity [157,158] (Table 1).
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Table 1. Fluorescent probes to detect ROS levels in platelets.
Probe Detected ROS Maximum ExcitationSpectra (nm)
Maximum Emission
Spectra (nm) Limitations and Artefacts References
CellROX® Green
H2O2
NO
ONOO−
O•2-
485 520 Antioxidants [158]
CellROX® Orange
H2O2
HO•
NO
ONOO−
O•2-
545 565 Antioxidants [158,159]
CellROX® Deep Red
O•2-
HO• 644 655 Antioxidants [159]
C11-BODIPY581/591
(membrane)
HO•
ROO• 488 520 Hemolysis Antioxidants [159,160]
DAF-FM NO 488 520 [161,162]
DCFH-DA/ DCF
HO•
ROO•
•NO
ONOO−
Indirectly H2O2
495 529
Hemolysis
Self-propagation of DCF radicals
Esterase inhibitors
Plasma esterase in whole blood or
PRP
EDTA and citrate Antioxidants
[157,163,164]
DHE/2OH-Et+ O•2- 400 580
Heme enzymes interference
Redox-cycling
Auto-oxidation
[151,165,166]
MitoSOXTM Red Mitochindrial O•2- 510 580 Mitochondria overload [151,167,168]
2OH-Et+: 2-hydroxy-ethidium; C11-BODIPY581/591: 4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a,4a-diaza-s-indacene-3-undecanoic acid; DAF-FM: 4-amino-5-
methylamino-2′,7′-difluorofluorescein diacetate; DCF: 2′,7′-dichlorofluorescein; DCFH-DA: dihydrochlorofluorescein diacetate; DCF: 2′,7′-dichlorofluorescein; DHE: dihydroethidium;
EDTA: ethylenediaminetetraacetic acid, H2O2: hydrogen peroxide; HClO: hypochlorous acid; HE: hydroethidine; MDR: multidrug resistance; NO•: nitrogen monoxide; NO•: nitrogen
dioxide; O•-: superoxide radical; HO•: hydroxyl radical; ONOO−: peroxynitrite; PRP: platelet-rich plasma; ROO•: peroxyl radicals.
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Specific kits are commercially available to monitor ROS levels in untreated platelets, in platelets
stimulated agonists or/and treated with NAC.
In general, these probes are non-fluorescent compounds which can passively diffuse into cells and,
upon interaction with intracellular ROS, are converted into fluorescent compounds. The fluorescence
signal is proportional to cellular ROS levels [169].
Dichlorodihy-drofluorescein diacetate (DCFH-DA) is commonly used for detecting H2O2 in cells
and in platelets. Once in the cell, it is hydrolyzed by intracellular esterases to DCFH which remains
trapped inside the cells. DCFH is oxidized by ROS/RNS, generally H2O2, becoming the fluorescent
2′,7′-dichlorofluorescein (DCF) detectable by FCM [163]. Dihydroethidium (DHE) has been suggested
as an alternative to DCFDA [165]. The detection of DHE oxidation derivates is generally performed by
liquid chromatography combined with mass spectrometry (LC–MS) [78]. Abubaker and colleagues
have recently developed and validated an alternative DHE probe-based technique for the detection, by
FCM, of O•2- in platelets. This technique is based on the intracellular detection of 2-hydroxy-ethidium
(2OH-Et+), the product of DHE oxidation by superoxide anions. The generation of 2OH-Et+, which
has an excitation peak at around 400 nm wavelength with emission at 580 nm, can be monitored
by FCM but also by confocal imaging and live imaging [166]. Robinson and colleagues have
reported that mitochondrial O•2- can be accurately quantified in live cells using FCM [167]. MitoSOX
is the mitochondrion-targeted form of DHE. Due to the positive charge of the cationic triphenyl
phosphonium substituent, MitoSOX is rapidly targeted to the mitochondria, where it is oxidized
by superoxide to form 2-hydroxymitoethidium, which is excited and emits at 510 and 580 nm,
respectively [167,168].
Furthermore, intracellular NO can be monitored by FCM with DAF-FM (4-amino-5-
methylamino-2′,7′-difluorofluorescein) diacetate, a pH-insensitive fluorescent dye that emits
fluorescence after reaction with an active intermediate of •NO, formed during the spontaneous
oxidation of •NO to NO2- [161]. Although DAF-FM has been primarily utilized to assess •NO
production by endothelial cells, it has been recently used to monitor •NO production by endothelial-like
NO synthase (eNOS) in platelets [162].
FCM has also been applied to lipid peroxidation detection.
The 4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora- 3a,4a-diaza-s-indacene-3-undecanoic acid
(C11-BOD- IPY581/591) is the main lipophilic dye used for lipid oxidation by oxyl-radical in leukocytes
and platelets [160]. Due to its lipophilic properties, C11-BOD- IPY581/591 passes through cell
membrane and, once inside, the polyunsaturated butadienyl portion of the dye is oxidized by
HO• or ROO• together with the endogenous fatty acids. When excited by blue light at 488 nm
wavelength, the molecule has a constitutive fluorescence emission with a maximum at 595 nm, but
after oxyl-radical induced oxidation by HO• or ROO•, the fluorescence emission shifts from red to
green with a maximum emission at 520 nm [159].
Several methodological limitations should be considered for FCM application in platelet ROS
detection. Basal levels of ROS should be measured only in fresh cells, as soon as possible, because of
the extremely low stability of ROS. Time-lapse from blood sampling, sample transport and isolation
may influence the results. Furthermore, the majority of probes are not designed to react with only
a specific type of ROS, and they often react with more than one ROS. For instance, DCFH is oxidized
by H2O2, but it can also interact with HO•, ROO•, •NO and ONOO−. DCFH oxidation can also be
promoted by Fe2+ in the presence of O2 or H2O2. It is also important to consider that some FCM
probes detecting ROS may also be sensitive to NO (for instance CellROX® Orange), which inhibits
platelet aggregation. Results could also be influenced by the experimental setting, such as incubation
temperature, probe concentration and uptake by the cell. Additionally, the presence of intracellular
probes per se could reduce platelet activation and ROS levels: elevated concentrations of probe may
induce cell morphology changes and artifacts in platelets. For example, an elevated concentration of
MitoSOX can overload and impair mitochondrial function [167].
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Some probes, such as DHE and DFCH-DA, require a two-step reaction to detect ROS. DFCH-DA
do not interact directly with H2O2, and must first be hydrolyzed by intracellular esterases. Therefore,
the presence of plasma esterase and esterase inhibitors [164] could potentially interfere with probe
staining and compromise the analysis of whole blood and platelet-rich plasma (PRP). In addition, DHE
and MitoSoX-based reactions implicate the formation of free-radical intermediates that can potentially
be a substrate for reaction with the antioxidants or induce a redox-cycling mechanism that leads to an
artificial amplification of the fluorescence signal [151].
Other potential approaches have been proposed to detect extracellular ROS. Some research
groups used a chemiluminescence method to detect platelet-released O•2-. Lucigenin
(N,N′-Dimethyl-9,9′-biacridinium dinitrate) and the luminol analog L-012 are the commonly used
chemiluminescent dyes. Superoxide levels might be artificially overestimated with these dyes, due
to the redox phenomenon in which lucigenin and L-012 radicals react with O2 to further generate
O•2- [37,170].
Platelet O•2- release can be evaluated by cytochrom-C assay. This method is based on reduction
of ferricytochrome C by O•2- to ferricytochrome C which is measured monitoring the absorbance
at 550 nm using a spectrophotometer [46,151]. The assay must be performed in the presence and in
the absence of SOD to determine the SOD-inhibitable signal and avoid artifacts. Since ferricytochrome
c is a large protein unable to pass through the cell membrane, this method is not suitable to detect O•2-
in the cytoplasm or in the mitochondria of intact cells [46,151].
Recently, Vara and coworkers developed a novel technique to simultaneously monitor platelet
activation and oxygen-radical generation. This multi-parametric analysis combined turbidimetry (for
platelet activation) with electron paramagnetic resonance (EPR) or EPR spectroscopy (for oxidative
status), and it could potentially find applications in clinical practice [49].
7.2. Detection of Antioxidant Enzymes Activity
Another common method, used to determine cellular and platelet redox state, is based on
the evaluation of ROS-generating and antioxidant enzyme profile, considering transcript and protein
levels by both RT-PCR and Western blot analysis [171]. As mentioned above, NOX and XO are
the main ROS sources in platelets, while the most important antioxidant enzymes are SOD, CAT, and
glutathione-dependent enzymes, such as GPX, GR, and glutathione transferases (GSTs) [35]. Since
mRNA and protein do not necessarily reflect enzymes activity, antioxidant enzyme expression must be
accompanied by enzyme biochemical activity evaluation.
Several assays, with high sensitivity, are now available and they are mainly based on colorimetric
reactions whose products can be estimated by absorbing the fluorescence relatively quickly. However,
methods based on more sophisticated tools, such as high-performance liquid chromatography, have
been developed [172]. SOD activity can be determined by a direct method based on H2O2 production
measurement [173] or by a spectrophotometric assay, which involves superoxide generation by
a xanthine/XO enzymatic system, superoxide-dependent reduction of cytochrome c or tetrazolium salt
WST-1 by O•2- to yellow colored formazan, and dose-dependent inhibition by SOD [174]. SOD activity
can also be detected semi-quantitatively using an in-gel activity assay, which employs a redox-sensitive
dye NBT as a detector of O•2-, and a non-enzymatic superoxide-generating photochemical reaction,
combined with polyacrylamide gel electrophoresis [175].
CAT-mediated H2O2 reduction can be measured by different colorimetric or spectrophotometric
assays, that measure the amount of unconverted H2O2 reacting with an OxiRedTM probe to generate
a final product. The change in H2O2 concentration is directly monitored following the decay in
absorbance at 240 nm [176]. GPX activity can be measured using cumene hydroperoxide and GSH
as substrates in a coupled reaction with GR. The GSSG formed during this reaction is converted to
the reduced state by GR in the presence of NADPH. The oxidation of NADPH, which is proportional
to the activity of GPX and GR, can be monitored spectrophotometrically at 340 nm [177].
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Furthermore, several assays have been proposed to assess GSH levels and GSH/GSSG ratio in
biological samples (spectrophotometry, HPLC, capillary electrophoresis, nuclear magnetic resonance,
and mass spectrometry). In platelet extracts, GSH /GSSG ratio is often evaluated using the GSH reductase
enzyme method. This assay consists of the thiol-mediated conversion of 5,5′-dithio-bis (2 nitrobenzoic
acid) (DTNB; Ellman’s reagent) to 5-thio-2-nitrobenzoic acid (TNB), monitored spectrophotometrically
at 412 nm. TNB formation is proportional to the concentration of GSH in the sample [178].
7.3. Detection of Protein Oxidation Products
Proteins represent a wide target for ROS, therefore protein oxidation has been considered an
indirect marker of oxidative stress. Several amino acidic residues can undergo oxidative modifications
including oxidation of sulphur-containing residues, hydroxylation of aromatic groups, nitration of
tyrosine residues, nitrosylation and glutathionylation of cysteine residues, conversion of some amino
acid residues to carbonyl derivatives. Several methods have been developed for the detection of
the different kinds of protein modifications; however, the ability to identify and quantify specific
protein oxidative modifications is still limited [159].
Given the relative stability of carbonylated proteins, the measure of carbonyl levels in proteins is
the most widely used marker of oxidative protein damage. Enzyme-linked immunosorbent assay
(ELISA) and HPLC are the most used methods for these purposes and the detection of protein carbonyl
groups generally involves the derivatization of the CO group with 2,4-dinitrophenylhydrazine (DNPH)
with the formation of a stable dinitrophenyl (DNP) hydrazone product. DND can be detected by several
methods which include the direct spectrophotometric measurement of DNP adducts, as well as more
specific techniques based on anti-DNP antibodies, like ELISA, Western blot after one-dimensional or
two-dimensional electrophoretic separation, immunohistochemistry, and HPLC [159]. The increase in
protein carbonylation has been reported in activated platelets and in platelet concentrates undergoing
platelet storage lesion [171]. Moreover, Alexandru and co-workers demonstrated that H2O2 produces
dose-dependent increase in the carbonylation of platelet proteins (vs. basal condition) and that
thrombin activation stimulates protein carbonyl formation in a process quenched by antioxidant
catalase [179].
3-nitro-tyrosine (3-NO-Tyr) is the main product of tyrosine oxidation and can be generated through
several pathways that include the reaction with ROS and RNS such as ONOO− and NO2 • [180–182].
3-NO-Tyr detection requires gas or liquid chromatographic techniques coupled to mass spectrometry;
moreover, ELISA assays based on specific antibodies are also available, despite their use being limited
by the variable affinity of antibodies to different nitrated proteins and the low sensitivity [183]. Very
few studies have measured platelet nitrotyrosine expression. Specifically, an increase in platelet
nitrotyrosine has been reported in a canine model of acute coronary syndromes [184] and in coronary
heart disease patients, but not in healthy donors, after ONOO- treatment [185].
7.4. Detection of Lipid Peroxidation
In addition to the described methods, the analysis of lipid peroxidation represents a different and
valid approach. Lipid peroxidation is widely used as a marker of oxidative stress in various cells,
including platelets. The increased generation of ROS may induce enhanced lipid peroxidation of cell
membrane phospholipids or circulating LDL leading to the increased generation of F2-isoprostanes,
a family of prostaglandin isomers produced from arachidonic acid by a mechanism catalyzed by free
radicals [186,187]. Lipid peroxidation, triggered by ROS, is an autocatalytic chain reaction, which
catalyzes the hydrogen subtraction at the unsaturated bonds generating a carbon-centered fatty radical
that can further react with oxygen producing a lipid peroxyl radical. Lipid peroxyl radicals induce
the formation of lipid hydroperoxides which, in the presence of transition metals, generate lipid
alkoxyl and ROO• as well as HO•. These products can further sustain the oxidation chain and
determine the production of malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE). The lipid
peroxyl radicals and final products of this process are both known to inhibit protein synthesis and
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alter enzymatic activity and chemotactic signals [188]. HNE can be detected by high-performance
liquid chromatography (HPLC), gas chromatography coupled with mass spectroscopy (GC-MS), and
immunological techniques using specific anti-HNE antibodies. The thiobarbituric acid assay (TBA test)
is a widely employed procedure to assess lipid oxidation. This assay is relatively simple, does not
require technical skills and it can be applied both on fresh and long-term stored platelets. The TBA
test is based on the reaction of MDA with thiobarbituric acid (TBA) which generates a pink adduct
complex, easily quantifiable by a colorimetric or fluorometric assay. Hemolysis and TBA unspecific
reaction with other several compounds can markedly compromise the assay, producing artifacts and
overestimating MDA measurement. Moreover, hemolysis can falsely increase the measured MDA
levels. Butyl hydroxytoluene (BHT) is usually added to cell lysate in order to prevent further MDA
generation during the procedure [189].
Another reliable marker of oxidative stress is represented by 8-isoprostane. 8-isoprostane is
the best characterized compound belonging to the F2-isoprostanes formed by free radical peroxidation
of biomembranes and then released in free form by phospholipase action. The reliable detection of
8-isoprostane in whole blood and platelet-rich plasma requires gas/liquid chromatography coupled with
mass spectroscopy techniques (HPLC/GC-MS) and it is affected by hemolysis. Immunoassay techniques,
based on specific antibodies, are under development, but their application is still limited [159].
7.5. Analysis of Mitochondrial Function
Mitochondrial dysfunction is often associated to oxidative-associated disorders and inflammatory
diseases [190–195]. Since platelets represent an accessible source of mitochondria, several research
groups have widely investigated bioenergetic platelet profile which might have potential clinical
applicability as a diagnostic and prognostic tool as well as a biomarker in treatment monitoring.
Many biochemical assays are available to determine the contribution of the mitochondrial ETC to
platelet activation. These assays include the expression analysis of the respiratory chain complexes by
Western blot or RT-PCR, measurement of the mitochondria membrane potential activity, ATP content
assay, and cytochrome c oxidase (complex IV) and succinate dehydrogenase (complex II) activity
using immunoassay or widespread spectrophotometric methods [196]. However, the evaluation of
the isolated complex expression and activity does not offer accurate data on the global respiratory
function, because ETC complexes are closely linked and depend on each other. In addition, these
assays cannot be performed on intact cells and in real time.
Intracellular oxygen concentration and oxygen consumption together with the other markers, such
as ATP content, mitochondrial membrane potential, reflect the respiratory activity and the bioenergetic
status of cells.
These parameters can be determined in platelets using a Clark oxygen electrode. This method has
been used with isolated mitochondria and platelets but showed several problems including uniform
signal drift, low sensitivity, changes in sensor response, and bubble formation on the electrode [197].
Recently, cell permeable fluorescent probes have been developed; some of them are based on
probe quenching by O2 resulting in a reduction in fluorescence or in O2-dependent red shift of
fluorescence [198].
Considering the increasing interest in cell metabolism and the need for an accurate and sensitive
method to assess mitochondrial oxidative phosphorylation function, two new systems have been
developed that allow monitoring cell respiration in response to external stimuli. These systems are
the high-resolution respirometry Oxygraph-2k (O2k, Oroboros Instruments, Austria) and the sensitive
high-throughput Seahorse XF Extracellular Flux Analyzer (Seahorse XF, Seahorse Bioscience Inc.).
Nowadays, both these methods are widely used for the evaluation of peripheral blood cells bioenergetics,
including platelets [135,199,200]. The O2k measures, in real time, the rapid changes in oxygen
concentration (nmol/mL) and oxygen consumption (pmol/sec/mL), both markers of OXPHOS, using
a polarographic sensors. It allows testing platelets response to a multitude of injectable reagents using
small quantities of initial sample. However, it requires constant monitoring and only two samples
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can be analyzed simultaneously, resulting in a very low throughput [201]. The extracellular flux
analyzer (XF) uses a novel fluorescent sensor-containing biocartridge to measure O2 consumption
rate (OCR), and extracellular acidification rate (ECAR), associated to mitochondria respiration and
glycolysis, respectively [199]. The system is fully automated, and it enables high-capacity sample
analysis, since a single plate with multiple samples can be analyzed with high resolution [201].
Mitochondrial bioenergetic profiles can be obtained measuring basal respiration and OCR/ECAR
after the injection of sequential injection of inhibitors of OXPHOS. The injection of oligomycin,
a specific inhibitor of the ATP synthase, induces a drastic reduction in OCR and it allows determining
the rate of oxygen consumption that corresponds to ATP synthesis, while the oligomycin-insensitive
rate is considered as proton leak across the inner mitochondrial membrane. FCCP (carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone), an uncoupler of the ETC, was used to determine
the maximal respiration rate. The difference between basal respiration and this FCCP-stimulated
OCR represents the reserve capacity of mitochondria, which corresponds to the maximal potential
respiratory capacity of cell under stress conditions and/or increased energetic demands. Antimycin A,
an inhibitor of complex III, is used to completely inhibit mitochondrial electron transport and to assess
non-mitochondrial oxygen consumption.
These advanced methods, coupled with analyses of oxidative stress markers and platelet
activation/aggregation assays could be useful for understanding platelet bioenergetic profiles in normal
and pathological conditions, but they still lack standardization to find applications in clinical routine.
8. Clinical Transferability
As outlined, platelet activation is influenced by the balance between oxidative stress and redox state.
However, the clinical implications of oxidative stress in platelet function and thrombosis are
still controversial.
So far, specific disease states that have been linked with platelet oxidative stress include obesity,
hypertension, insulin resistance and type II diabetes. Overall, these are all part of the so-called
metabolic syndrome. Obese and hypertensive patients typically show activated circulating platelets,
increased platelet aggregation and formation of platelet-leukocyte aggregates, enhanced endogenous
ROS production and reduced antioxidant status, NOS activity and NO bioavailability [202,203].
In type II diabetic patients, intracellular calcium homeostasis is compromised, probably due to
increased hydrogen peroxide and peroxyl radical levels, leading to platelet hyper-reactivity and
hyper-aggregability [204]
Given this scenario, the antioxidant activity of natural compounds has been investigated in
order to contrast platelet endogenous oxidative stress and associated cardiovascular diseases. These
compounds include not only well-known molecules with widely investigated antioxidant properties
such as polyphenols and flavonoids—which appear to also be active in platelet-related oxidative
stress—but also other novel bioactive plant components.
The protective effects of the polyphenolic and flavonoid-rich extract from berries of Aronia
Melanocarpa (containing anthocyanidines, phenolic acids and quercetin glycosides) on platelet
oxidative-stress biomarkers have been investigated by Kedzierska et al. [205] and Olas et al. [206].
The first work the analyzed oxidative/nitrative modifications of blood platelet proteins in breast
cancer patients, by measuring the level of biomarkers of oxidative/nitrative stress such as carbonyl
groups, thiol groups and 3-nitrotyrosine. The authors demonstrated that the polyphenol rich extract
of A.Melanocarpa is capable, in vitro, to reduce thiol groups and 3-nitrotyrosine in platelet proteins,
therefore counteracting platelet oxidative stress induced by cancer. This compound proved to be active
also in the reduction of other platelet oxidative markers, namely the level of 8-epi-prostaglandin F(2)
and glutathione amount, together with platelet activation markers, such as GPαIIbβ3 [206].
Based on these findings, Sikora et al. [207] investigated the effects of dietary supplementation with
A. Melanocarpa extract on platelet aggregation, clot formation, and lysis in patients with metabolic
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syndrome. After 1 month, the authors observed an inhibition of platelet aggregation and a beneficial
reduction in the overall potential for clot formation and fibrinolysis.
Argan oil produced an antioxidant effect by reducing platelet malondialdehyde levels, and
increasing platelet glutathione peroxidase activity [208]. Experiments in rats indicated that treatment
of platelets by argan oil (0.2, 0.5, 1, and 2%) prevents platelet aggregation induced in vitro and ex vivo
by thrombin or epinephrine [209].
Aqueous extract of medicinal plant Conyza canadensis acts as a free radical scavenger, reducing
O2− generation, and inhibiting the oxidation and nitration of proteins in blood platelets treated with
peroxynitrite ONOO− [210].
Finally, Cinnamtannin B1, found in Cinnamomum verum, is a type A proanthocyanidin which
exerts an effective antioxidant action through the inhibition of endogenous ROS generation in platelets
derived from type II diabetic patients [211,212].
Advances in the knowledge of the functional role of ROS in platelet biology and the mechanism
of action of plants with antiplatelet effect will hopefully provide new approaches to develop
pharmaceutical strategies to promote cardiovascular health.
9. Conclusions
Strict relationships between platelet functions and redox state exist. Indeed, platelets are both
a source and target of ROS and a fine balance between ROS production and ROS detoxification divide
platelet physiology from pathology. Changes in redox status occur during platelet activation, and
several platelet activation pathways lead to intraplatelet ROS production, primarily via NOX and
mitochondria. In turn, platelet-derived ROS, as well as ROS/RNS, act as second messengers and can
influence different signaling pathways, which enhance agonist-induced platelet functions and promote
platelet recruitment and aggregation. Therefore, enzymatic and non-enzymatic antioxidant systems
have a key role to prevent cytotoxic effects of ROS and to regulate redox-sensitive signaling pathways
in platelets.
Platelet redox systems have important clinical implications. Of note, several pathological
conditions show both altered platelet function and imbalance of redox homeostasis; both these aspects
are often part of a vicious circle that may lead to serious consequences. Platelet redox status looks to
be a promising biomarker, as well as a good candidate target for cardiovascular and inflammatory
diseases prevention and treatment.
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Abbreviations
•NO nitric oxide
•NO2 nitrogen dioxide radical
•OH hydroxyl radical
∆Ψm mitochondrial membrane potential
2OH-Et+ 2-hydroxy-ethidium
3-NO-Tyr 3-nitro-tyrosine
8-iso-PGF2α 8-iso-prostaglandin F2α
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αIIbβ3 glycoprotein GPIIb/IIIa
AA arachidonic acid
ADP adenosine diphosphate
ADAM disintegrin and metalloproteinase
AMI acute myocardial infarction
BHT butyl hydroxytoluene
C11-BODIPY581/591
4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a,
4a-diaza-s-indacene-3-undecanoic acid
CAA cerebrovascular amyloid angiopathy
CaM calmodulin
CAT catalase
CD40L CD40 ligand
CD62p P-selectin
COX cyclooxygenase
DAF-FM 4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate
DCF 2′,7′-dichlorofluorescein
DCFH-DA dihydrochlorofluorescein diacetate
DHE dihydroethidium
DNDPH 2,4-dinitrophenylhydrazine
DNP dinitrophenyl
DPI diphenyleneiodonium cloride
DTNB 5,5′-dithio-bis (2 nitrobenzoic acid)
ECAR extracellualr acidification rate
EDTA ethylenediaminetetraacetic acid
ELISA enzyme-linked immunosorbent assay
eNOSIII endothelial-like NO synthase III
EPR electron paramagnetic resonance
ETC electron transport chain
FAD flavin adenine dinucleotide
FCCP carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
FCM flow cytometry
FcRγ Fc receptor γ-chain
GC-MS gas chromatography coupled with mass spectroscopy
GPIbα glycoprotein Ibα
GPVI glycoprotein VI
GPx glutathione peroxidase
GSH glutathione
GSSG glutathione disulfide
GST glutathione S-transferase
H2O2 hydrogen peroxide
HClO hypochlorous acid
HE hydroethidine
Hic-5 focal adeshion adapter protein
HNE 4-hydroxy-2-nonenal
HO-1 heme oxygenase 1
HPLC high-performance liquid chromatography
IP3 inositol 1,4,5-trisphosphate
ITAM immunoreceptor tyrosine-based activation motif
LC-MS liquid chromatography mass spectrometry
MAPKp38 P38 mitogen-activated protein kinases
MDA malondialdehyde
MDR multidrug resistance
MKs megakaryocytes
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mPTP mitochondrial permeability transition pore
NAC N-acetylcysteine
NAD(P)H nicotinamide adenine dinucleotide (phosphate)
NO-GC NO-sensitive guanylyl cyclase
NOS nitric oxide synthase
Nrf2-Keap1
nuclear factor eruthroid-2 related factor 2/kelch-like
ECH-associated protein
O•2- superoxide anion
O2 molecular oxygen
O2K Oxygraph-2k
OCR O2 consumption rate
OH− hydroxyl ion
ONOO- peroxynitrite
Ox-LDL oxidized low-density lipoprotein
OXPHOS oxidative phosphorylation
P2Y1 and P2Y12 purinergic G protein-coupled receptors
PAR1 and PAR4 protease activated receptors
PDIs platelet disulfide isomerase
PGH2 prostaglandin H2
PI(3,4)P phosphatidylinositol 3,4-biphosphate
PI3K phosphatidylinositol 3-kinase
PKC protein kinase C
PLA2 phospholipase A2
PLCγ2 phospholipase Cγ2
PLTs platelets
PRP platelet-rich plasma;
PrxII peroxiredoxin II
PS phosphatidylserine
Pyk2 proline rich tyrosine kinase 2
RNS reactive nitrogen species
ROO• peroxyl radicals
ROS Reactive oxygen species
sCD40L Soluble CD40 ligand
SH3 Src homology-3
SHP-2
Src homology region 2-containing protein tyrosine
phosphatases 2
SOD1/2 superoxide dismutase 1/2
Syk spleen tyrosine kinase
TBA thiobarbituric acid
TNB 5-thio-2-nitrobenzoic acid
TP thromboxane receptor
TRAF4 tumor nescrosis factor associated factor 4
Trx thioredoxin
TXA2 thromboxane A2
U46619 thromboxane A2 analog
VWR von Willebrand factor
X-linked CGD X-linked chronic granulomatous disease
XF extracellular flux analyzer
XO xanthine oxidase
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